Geron Corporation (GERN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.30 (-1.52%), Market cap $0.81B, 52-week low–high $1.07 ~ $1.95.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatm
Financial statements, price targets, institutional (13F) holdings and related news for Geron Corporation are updated in real time on BlackAll Trade.
Geron Corporation trades at $1.30 (-1.52%). Real-time quotes and charts are available on BlackAll Trade.
Geron Corporation has a market cap of about $0.81B.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibito